Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Penumbra, Inc. Reports Third Quarter 2017 Financial Results

      Penumbra, Inc. Logo (PRNewsFoto/Penumbra, Inc.)

      News provided by

      Penumbra, Inc.

      Nov 07, 2017, 15:05 ET

      Share this article

      Share this article


      ALAMEDA, Calif., Nov. 7, 2017 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the third quarter ended September 30, 2017.

      • Revenue of $83.9 million in the third quarter of 2017, an increase of 24.9%, or 24.1% in constant currency1, over the third quarter of 2016.

      Third Quarter 2017 Financial Results
      Total revenue grew to $83.9 million for the third quarter of 2017 compared to $67.2 million for the third quarter of 2016, an increase of 24.9%, or 24.1% on a constant currency basis. The United States represented 66% of total revenue and international represented 34% of total revenue for the third quarter of 2017. Revenue from sales of neuro products grew to $58.7 million for the third quarter of 2017, an increase of 23.4%, or 22.5% on a constant currency basis, from the third quarter of 2016. Revenue from sales of peripheral vascular products grew to $25.2 million for the third quarter of 2017, an increase of 28.4%, or 27.8% on a constant currency basis, from the third quarter of 2016.

      Gross profit was $54.8 million, or 65.3% of total revenue, for the third quarter of 2017, compared to $42.9 million, or 63.8% of total revenue, for the third quarter of 2016.

      Total operating expenses were $54.1 million, or 64.5% of total revenue, for the third quarter of 2017, compared to $44.2 million, or 65.8% of total revenue, for the third quarter of 2016. R&D expenses were $8.1 million for the third quarter of 2017, compared to $6.5 million for the third quarter of 2016. SG&A expenses were $46.0 million for the third quarter of 2017, compared to $37.7 million for the third quarter of 2016.

      Operating income for the third quarter of 2017 was $0.7 million, compared to operating loss of $1.4 million for the third quarter of 2016. Operating income for the third quarter of 2017 benefited from a $1.2 million net refund of previously paid medical device excise tax.

      Full Year 2017 Financial Outlook
      The Company is increasing its 2017 guidance for total revenue to be in the range of $324 million to $326 million. This new range compares to the previous range of $312 million to $317 million.

      Webcast and Conference Call Information
      Penumbra, Inc. will host a conference call to discuss the third quarter 2017 financial results after market close on Tuesday, November 7, 2017 at 5:00 PM Eastern Time. The conference call can be accessed live over the phone by dialing (866) 393-4306 for domestic callers or (734) 385-2616 for international callers (conference id: 99307870), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for two weeks following the completion of the call.

      About Penumbra
      Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on interventional therapies. Penumbra designs, develops, manufactures and markets innovative devices and has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc.

      Non-GAAP Financial Measures
      In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses results on constant currency as a non-GAAP financial measure in this press release.

      Our constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.

      Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.

      Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations.

      The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

      Forward-Looking Statements
      Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 28, 2017. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.





      1 Constant currency results are non-GAAP financial measures. Please refer to "Non-GAAP Financial Measures" herein for important information about our use of constant currency results (including reconciliations to the most comparable GAAP measures).

      Penumbra, Inc.

      Condensed Consolidated Balance Sheets

      (unaudited)

      (in thousands)




      September 30,

       2017


      December 31,

       2016

      Assets





      Current assets:





           Cash and cash equivalents


      $

      65,621



      $

      13,236


           Marketable investments


      153,203



      115,517


          Accounts receivable, net


      47,964



      43,335


           Inventories


      90,529



      73,012


           Prepaid expenses and other current assets


      14,464



      18,727


                Total current assets


      371,781



      263,827


      Property and equipment, net


      28,259



      21,464


      Intangible assets, net


      23,821



      —


      Goodwill


      7,449



      —


      Deferred taxes


      22,503



      22,476


      Other non-current assets


      5,281



      487


               Total assets


      $

      459,094



      $

      308,254


      Liabilities and Stockholders' Equity





      Current liabilities:





           Accounts payable


      $

      5,768



      $

      4,110


           Accrued liabilities


      45,312



      31,690


                Total current liabilities


      51,080



      35,800


      Deferred rent


      6,065



      5,083


      Other non-current liabilities


      18,117



      824


                Total liabilities


      75,262



      41,707


      Stockholders' equity:





      Common stock


      33



      31


      Additional paid-in capital


      389,682



      273,865


      Accumulated other comprehensive income (loss)


      1,204



      (4,688)


      Accumulated deficit


      (7,087)



      (2,661)


           Total stockholders' equity


      383,832



      266,547


                Total liabilities and stockholders' equity


      $

      459,094



      $

      308,254


      Penumbra, Inc.

      Condensed Consolidated Statements of Operations

      (unaudited)

      (in thousands, except share and per share amounts)




      Three Months Ended September 30,


      Nine Months Ended September 30,



      2017


      2016(1)


      2017


      2016(1)

      Revenue


      $

      83,911



      $

      67,187



      $

      237,713



      $

      190,212


      Cost of revenue


      29,134



      24,313



      84,298



      65,963


      Gross profit


      54,777



      42,874



      153,415



      124,249


      Operating expenses:









      Research and development


      8,132



      6,497



      23,260



      17,762


      Sales, general and administrative


      45,962



      37,740



      132,846



      106,685


      Total operating expenses


      54,094



      44,237



      156,106



      124,447


      Income (loss) from operations


      683



      (1,363)



      (2,691)



      (198)


      Interest income, net


      658



      631



      1,926



      1,700


      Other expense, net


      (647)



      (360)



      (1,368)



      (856)


      Income (loss) before income taxes


      694



      (1,092)



      (2,133)



      646


      Provision for (benefit from) income taxes


      456



      (12,998)



      2,293



      (16,564)


      Net income (loss)


      $

      238



      $

      11,906



      $

      (4,426)



      $

      17,210


      Net income (loss) per share

      —Basic


      $

      0.01



      $

      0.39



      $

      (0.14)



      $

      0.57


      —Diluted


      $

      0.01



      $

      0.35



      $

      (0.14)



      $

      0.52


      Weighted average shares used to compute net income (loss) per share

       —Basic


      33,446,841



      30,604,384



      32,766,135



      30,269,463


      —Diluted


      35,664,272



      33,755,383



      32,766,135



      33,367,618








      1 We elected to early adopt ASU 2016-09 in the fourth quarter of 2016. Our condensed consolidated statement of operations for the three and nine months ended September 30, 2016 was adjusted to include the impact of ASU 2016-09 adoption. See Notes 2 and 15 in the notes to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 28, 2017 for detailed adoption information.

      Penumbra, Inc.

      Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1

      (unaudited)

      (in thousands)




      Three Months Ended September 30,


      Reported Change


       FX Impact


      Constant Currency Change



      2017


      2016


      $


      %


      $


      $


      %

      United States


      $

      55,652



      $

      44,380



      $

      11,272



      25.4

      %


      $

      —



      $

      11,272



      25.4

      %

      International


      28,259



      22,807



      5,452



      23.9

      %


      (555)



      4,897



      21.5

      %

      Total


      $

      83,911



      $

      67,187



      $

      16,724



      24.9

      %


      $

      (555)



      $

      16,169



      24.1

      %


      Penumbra, Inc.

      Reconciliation of Revenue Growth by Product Categories to Constant Currency Revenue Growth1

      (unaudited)

      (in thousands)




      Three Months Ended September 30,


      Reported Change


       FX Impact


      Constant Currency Change



      2017


      2016


      $


      %


      $


      $


      %

      Neuro


      $

      58,670



      $

      47,534



      $

      11,136



      23.4

      %


      $

      (424)



      $

      10,712



      22.5

      %

      Peripheral Vascular


      25,241



      19,653



      5,588



      28.4

      %


      (131)



      5,457



      27.8

      %

      Total


      $

      83,911



      $

      67,187



      $

      16,724



      24.9

      %


      $

      (555)



      $

      16,169



      24.1

      %


      Penumbra, Inc.

      Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1

      (unaudited)

      (in thousands)




      Nine Months Ended September 30,


      Reported Change


       FX Impact


      Constant Currency Change



      2017


      2016


      $


      %


      $


      $


      %

      United States


      $

      157,559



      $

      127,484



      $

      30,075



      23.6

      %


      $

      —



      $

      30,075



      23.6

      %

      International


      80,154



      62,728



      17,426



      27.8

      %


      315



      17,741



      28.3

      %

      Total


      $

      237,713



      $

      190,212



      $

      47,501



      25.0

      %


      $

      315



      $

      47,816



      25.1

      %


      Penumbra, Inc.

      Reconciliation of Revenue Growth by Product Categories to Constant Currency Revenue Growth1

      (unaudited)

      (in thousands)




      Nine Months Ended September 30,


      Reported Change


       FX Impact


      Constant Currency Change



      2017


      2016


      $


      %


      $


      $


      %

      Neuro


      $

      165,122



      $

      134,180



      $

      30,942



      23.1

      %


      $

      235



      $

      31,177



      23.2

      %

      Peripheral Vascular


      72,591



      56,032



      16,559



      29.6

      %


      80



      16,639



      29.7

      %

      Total


      $

      237,713



      $

      190,212



      $

      47,501



      25.0

      %


      $

      315



      $

      47,816



      25.1

      %


      1See "Non-GAAP Financial Measures" above for important information about our use of this non-GAAP measure and further information about our calculation of constant currency results.

      Investor Relations
      Penumbra, Inc.
      510-995-2461
      [email protected]

      SOURCE Penumbra, Inc.

      Modal title

      Also from this source

      Penumbra, Inc. Reports Third Quarter 2026 Financial Results

      Penumbra, Inc. Reports Third Quarter 2026 Financial Results

      Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026....

      Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

      Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

      Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.